hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"

NCT03824691 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

122

Enrollment

OTHER

Sponsor class

Conditions

Bladder Carcinoma

Interventions

DRUG: Cabozantinib
DRUG: Durvalumab

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano